Valerio Therapeutics (ALVIO) AI Stock Analysis

• Market Cap: €20.14M
• Dividend Yield: N/A
• Average Volume (3M): 48.22K
• Price to Earnings (P/E): ―
• Beta (1Y): -0.34
• Revenue Growth: -0.39%
• EPS Growth: 3.51%
• Country: FR
• Employees: 38
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): N/A
• Shares Outstanding: 350,507,930
• 10 Day Avg. Volume: 48,038
• 30 Day Avg. Volume: 48,222
• PEG Ratio: -0.07
• Price to Book (P/B): -1.29
• Price to Sales (P/S): 6.44
• P/FCF Ratio: -0.90
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: €0.01
• Price Target Upside: -83.33% Downside
• Rating Consensus: Hold
• Number of Analyst Covering: 0

• Rating: 43 Neutral
• Price Target: €0.00 ▼(-100.00% Downside)

Valerio Therapeutics is facing significant financial challenges, with declining revenues and negative profitability margins being the most impactful factors. The technical analysis shows neutral indicators, while the valuation is unattractive due to a negative P/E ratio and no dividend yield. These factors collectively result in a low overall stock score.

Valerio Therapeutics Business Overview & Revenue Model

Company Description

Valerio Therapeutics Société anonyme, a clinical-stage biotechnology company, designs and develops oncology drugs for tumor DNA repair functions worldwide. The company offers Beleodaq for the treatment of peripheral T-cell lymphoma. It also develops AsiDNA, which is in Phase 1 clinical trial for the treatment of metastatic melanoma; OX401, which is in preclinical stage for treating DNA damage response and immuno-oncology; and platON, a decoy oligonucleotide platform. It has a license agreement with Acrotech Biopharma LLC; and clinical research agreement with Gustave Roussy to conduct clinical trial of AsiDNA for the treatment of relapsed ovarian cancer. The company was formerly known as Onxeo SA and changed its name to Valerio Therapeutics Société anonyme in June 2023. Valerio Therapeutics Société anonyme was incorporated in 1997 and is headquartered in Paris, France.

How the Company Makes Money

Valerio Therapeutics generates revenue primarily through the development and commercialization of its therapeutic products. This includes income from collaborations and partnerships with pharmaceutical companies that may involve licensing agreements, milestone payments, and royalties on sales of products developed through these collaborations. Additionally, the company may receive funding from grants and public investments aimed at supporting innovative healthcare solutions. The successful advancement of its drug candidates through clinical trials and eventual market approval plays a critical role in the company's financial performance.

Valerio Therapeutics Financial Statement Overview

Summary

Valerio Therapeutics faces significant financial challenges, with declining revenues, negative profitability margins, and high leverage. The negative equity and cash flow issues further highlight financial instability.

Income Statement

Valerio Therapeutics shows declining revenue with a negative revenue growth rate of -5.08% in the latest year. The gross profit margin is relatively strong at 71.39%, but the company suffers from significant net losses, reflected in a net profit margin of -13.35%. The EBIT and EBITDA margins are also negative, indicating operational challenges.

Balance Sheet

The company has a negative stockholders' equity, leading to a concerning debt-to-equity ratio of -1.50. This indicates financial instability and high leverage. The return on equity is positive at 2.68%, but this is due to the negative equity, which is not a healthy sign.

Cash Flow

Valerio Therapeutics has negative operating and free cash flows, with a free cash flow growth rate of -22.25%. The operating cash flow to net income ratio is negative, indicating cash flow issues. However, the free cash flow to net income ratio is slightly above 1, suggesting that free cash flow is somewhat aligned with net income.

Breakdown	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	1.79M	1.80M	1.44M	4.06M	1.78M
Gross Profit	1.28M	1.27M	929.00K	3.69M	1.43M
EBITDA	-12.06M	-18.44M	-17.04M	-5.86M	2.33M
Net Income	-23.93M	-20.34M	-19.56M	-5.94M	1.09M
Balance Sheet
Total Assets	17.93M	35.27M	43.09M	53.06M	46.51M
Cash, Cash Equivalents and Short-Term Investments	1.18M	6.82M	14.59M	17.89M	14.52M
Total Debt	13.44M	9.00M	10.09M	9.94M	6.26M
Total Liabilities	26.19M	20.47M	20.82M	20.12M	17.47M
Stockholders Equity	-8.93M	14.80M	22.27M	32.94M	29.04M
Cash Flow
Free Cash Flow	-12.78M	-18.78M	-9.93M	-8.71M	-4.80M
Operating Cash Flow	-12.46M	-18.60M	-9.44M	-8.57M	-4.68M
Investing Cash Flow	-1.39M	-177.00K	-409.00K	-66.00K	6.01M
Financing Cash Flow	4.21M	10.76M	6.46M	11.98M	7.48M

Valerio Therapeutics Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 0.06
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For FR:ALVIO, the sentiment is Neutral. The current price of 0.06 is above the 20-day moving average (MA) of 0.06, below the 50-day MA of 0.06, and below the 200-day MA of 0.06, indicating a bearish trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 43.10 is Neutral, neither overbought nor oversold. The STOCH value of 27.78 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for FR:ALVIO.

Valerio Therapeutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
ALTHX	52 Neutral	€19.88M	―	―	―	―	10.28%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
ALTME	50 Neutral	€10.69M	―	―	―	―	―
ALVIO	43 Neutral	€20.14M	―	-814.67%	―	-0.39%	3.51%